Diabetes

If approved, KnowU will become the world’s first non-invasive blood glucose monitor introduced to the global marketplace.

As acute and chronic diabetes complications increase, particularly among younger and socioeconomically disadvantaged populations, out-of-pocket costs remain a barrier to accessing essential medications.

Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).

A new study found that over a quarter of participants with type 1 daiebets exhibited clinically relevant levels of posttraumatic stress symptoms related to a diabetes event that they experienced.

Although diabetes mortality rates were stable in the Americas over the past 2 decades, the actual number of diabetes-related deaths is rising.

Investigators found that the non-pharmacological interventions were significantly effective at improving HbA1c, quality of life, anxiety, and blood glucose.

A recent study found that patients with pre-gestational diabetes reported higher levels of both borderline and abnormal anxiety compared to patients with gestational diabetes.

Smartphone apps were effective at promoting weight loss and reducing BMI, but had no impact on HbA1c levels or waist circumference.

A study found that patients with type 2 diabetes who showed evidence of any remission had a 33% lower rate of chronic kidney disease, and a 40% lower rate of the composite cardiovascular disease measure.

Compared with an HbA1c level of 5.5%, adolescents with overweight or obesity were 72 times more likely to have type 2 diabetes if their HbA1c was 6.3% to 6.4%.

Through interactive lessons, skill-building modules and weekly goal setting and tracking, AspyreRx allows patients to connect changes in behavior to improvements in blood sugar and other biometrics.

By getting involved in patient care, pharmacists can help alleviate the burdens associated with the self-management of type 2 diabetes (T2D).

Patients using a predictive alarm saw a reduction of more than 40% in time spent below range in hypoglycemia and more than 60% in time spent in severe hypoglycemia.

The proprietary disposable insulin delivery system promises to be a more convenient, individualized, and accessible treatment option for patients with diabetes.

Regulators will continue to conduct additional evaluations to assess the link between GLP-1 drugs and suicidal thoughts or actions.

These findings can help health care professionals develop a family-centered treatment plan for pediatric type 1 diabetes, considered a “family disease” by study authors.

Results from a meta-analysis demonstrated that magnesium supplementation was able to decrease fasting glucose levels and improve insulin resistance.

A study found that patients living in a food desert and in a less walkable neighborhood had an increased risk of gestational diabetes.

Patients on a moderate carbohydrate diet increased their time in range by 4.7% and decreased their time above range by 5.9%.

Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.

Study findings shed light on the disproportionate burden of type 2 diabetes (T2D) and colorectal cancer faced by individuals with low socioeconomic status and those of African American race.

Two posters presented at ASHP Midyear 2023 explored the impact of diabetes management interventions among patients with diabetes.

Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.

A new systematic review and meta-analysis found that the risk of type 2 diabetes decreased significantly at walking speeds of 4 km/h or above.

An analysis on the Diabetes Prevention Program in England found it was effective at improving key cardiovascular risk factors, including glycated hemoglobin and excess body weight.

Because of misclassification of diabetes type and the absence of distinction between risk factors, such as birth weight, and diabetes type, uncertainty exists regarding the relationship between obesity and T1D.

The drug, Zepbound, will be available in the United States by the end of 2023.

A poster presented at AMCP Nexus 2023 outlined how a Pharmacy Therapeutics program yielded $7,500 in savings per patient and $3.5 million in savings overall by reducing patients' incretin therapy prescriptions from two to one.